The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

Monoclonal antibody nirsevimab provides strong real-world protection against severe RSV in infants, suggests meta-analysis ...

A monoclonal antibody — a protein created in a lab which mimics the work of a natural antibody — could be highly effective in ...

"Nirsevimab is highly effective in preventing RSV-related outcomes in infants, with a pooled real-world effectiveness of 83 ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

The monoclonal antibody nirsevimab, designed to mimic natural antibodies, significantly reduces severe RSV-related ...

Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial ...

Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial virus (RSV) infections in infants, suggests a meta-analysis published in The ...

Dr Reddy’s Laboratories on Monday said it has expanded its strategic partnership with French biopharma giant Sanofi’s Indian ...

Dr Reddy’s & Sanofi Healthcare expand partnership to unveil Beyfortus, a novel drug to prevent RSV in India: Our Bureau, Bengaluru Tuesday, April 29, 2025, 12:15 Hrs [IST] Dr Re ...